300 mg [C14] CT1812
COG0108
Phase 1 small_molecule completed
Quick answer
300 mg [C14] CT1812 for Alzheimer Disease is a Phase 1 program (small_molecule) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- COGNITION THERAPEUTICS INC
- Indication
- Alzheimer Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed